Global Fabry Disease Treatment Market to Reach $4.41 Billion by 2030, Driven by Leading Drugs and Emerging Pipeline Therapies
• Global Fabry disease treatment market valued at $2.50 billion in 2023, projected to reach $2.71 billion in 2024 and $4.41 billion by 2030
• Chaperone Treatment and Enzyme Replacement Therapy dominate treatment types
• Agalsidase beta and migalastat are leading drugs, with growing interest in pipeline drugs
• Market has presence across Americas, Asia-Pacific, Europe, Middle East & Africa
• Key players include Amicus Therapeutics, Avrobio Inc., BioMarin, GlaxoSmithKline, Idorsia Pharmaceuticals, Nestle Health Science, Pfizer Inc., Sanofi